Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment and immune-mediated conditions, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's leadership, including President and CEO Daniel J. Hicklin, Ph.D., and Chief Medical Officer Randi Isaacs, M.D., will deliver a corporate overview on Monday, April 7, 2025, at 1:30 PM ET. The conference is scheduled for April 7-10, 2025.
Interested parties can access the live presentation through the company's investor relations website at investors.werewolftx.com/news-and-events/events. A replay will remain available for approximately 90 days after the event.
Werewolf Therapeutics (Nasdaq: HOWL), una compagnia biofarmaceutica focalizzata nello sviluppo di terapie attivate in modo condizionale per il trattamento del cancro e delle condizioni mediate dal sistema immunitario, ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
La leadership dell'azienda, inclusi il Presidente e CEO Daniel J. Hicklin, Ph.D. e il Chief Medical Officer Randi Isaacs, M.D., presenterà una panoramica aziendale lunedì 7 aprile 2025, alle 13:30 ET. La conferenza è in programma dal 7 al 10 aprile 2025.
Le parti interessate possono accedere alla presentazione dal vivo tramite il sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.werewolftx.com/news-and-events/events. Una registrazione sarà disponibile per circa 90 giorni dopo l'evento.
Werewolf Therapeutics (Nasdaq: HOWL), una empresa biofarmacéutica centrada en el desarrollo de terapias activadas condicionalmente para el tratamiento del cáncer y condiciones mediadas por el sistema inmunológico, ha anunciado su participación en la próxima 24ª Conferencia Virtual Anual de Needham sobre Salud.
El liderazgo de la empresa, incluyendo el Presidente y CEO Daniel J. Hicklin, Ph.D. y la Directora Médica Randi Isaacs, M.D., ofrecerá una visión general corporativa el lunes 7 de abril de 2025, a la 1:30 PM ET. La conferencia está programada del 7 al 10 de abril de 2025.
Las partes interesadas pueden acceder a la presentación en vivo a través del sitio web de relaciones con inversores de la empresa en investors.werewolftx.com/news-and-events/events. Una grabación estará disponible durante aproximadamente 90 días después del evento.
Werewolf Therapeutics (Nasdaq: HOWL)는 암 치료 및 면역 매개 질환을 위한 조건부 활성화 치료제를 개발하는 데 집중하는 생명공학 회사로, 다가오는 제24회 니드햄 연례 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 경영진, 즉 회장 겸 CEO 다니엘 J. 히클린 박사와 최고 의료 책임자 랜디 아이작스 박사가 2025년 4월 7일 월요일 오후 1시 30분 ET에 기업 개요를 발표할 예정입니다. 이 컨퍼런스는 2025년 4월 7일부터 10일까지 예정되어 있습니다.
관심 있는 분들은 회사의 투자자 관계 웹사이트인 investors.werewolftx.com/news-and-events/events를 통해 라이브 프레젠테이션에 접근할 수 있습니다. 이벤트 후 약 90일 동안 재생이 가능합니다.
Werewolf Therapeutics (Nasdaq: HOWL), une entreprise biopharmaceutique axée sur le développement de thérapies activées de manière conditionnelle pour le traitement du cancer et des conditions médiées par le système immunitaire, a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
La direction de l'entreprise, y compris le Président et PDG Daniel J. Hicklin, Ph.D. et la Directrice Médicale Randi Isaacs, M.D., présentera un aperçu de l'entreprise le lundi 7 avril 2025, à 13h30 ET. La conférence est prévue du 7 au 10 avril 2025.
Les parties intéressées peuvent accéder à la présentation en direct via le site Web des relations avec les investisseurs de l'entreprise à l'adresse investors.werewolftx.com/news-and-events/events. Un enregistrement sera disponible pendant environ 90 jours après l'événement.
Werewolf Therapeutics (Nasdaq: HOWL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von bedingt aktivierten Therapeutika zur Behandlung von Krebs und immunvermittelten Erkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben.
Die Unternehmensleitung, einschließlich Präsident und CEO Daniel J. Hicklin, Ph.D. und Chief Medical Officer Randi Isaacs, M.D., wird am Montag, den 7. April 2025, um 13:30 Uhr ET eine Unternehmensübersicht präsentieren. Die Konferenz ist für den 7. bis 10. April 2025 geplant.
Interessierte Parteien können die Live-Präsentation über die Investor-Relations-Website des Unternehmens unter investors.werewolftx.com/news-and-events/events abrufen. Eine Aufzeichnung wird etwa 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will present a corporate overview at 1:30 PM ET on Monday, April 7, 2025, at the 24th Annual Needham Virtual Healthcare Conference, taking place on April 7–10, 2025.
A live webcast link for the presentation will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the Needham Healthcare Conference 2025?
How long will the HOWL presentation replay be available for viewing?
What therapeutic focus does Werewolf Therapeutics (HOWL) specialize in?
Which executives from Werewolf Therapeutics (HOWL) will present at the Needham Conference?
Where can investors watch the HOWL presentation at the Needham Healthcare Conference?
